Clinical Report: The Changing Role of Analytical Science in Drug Discovery
Overview
Analytical science is evolving in drug discovery, with advancements in data generation and automation. The integration of more physiologically relevant models presents challenges in data consistency and reproducibility.
Background
The role of analytical science in drug discovery is critical as it underpins the development of novel therapeutics and informs regulatory decisions. The increasing complexity of biological models introduces challenges in data reliability.
Data Highlights
No numerical or trial data provided in the source material.
Key Findings
- Analytical science is generating richer datasets that inform earlier decision-making in drug discovery.
- Automation improves consistency in handling complex biological models.
- Complex models introduce challenges in data reproducibility.
- Advancements in analytical technologies enhance the reliability of data generated from biological systems.
- AI and automated workflows enable the evaluation of more conditions and larger datasets.
Clinical Implications
Automation can help manage variability in drug discovery.
Conclusion
The changing landscape of analytical science in drug discovery highlights the need for advancements in automation and data analysis.
Related Resources & Content
- Farley M. M., SLAS, 2023 -- The Changing Role of Analytical Science in Drug Discovery
- the analytical scientist — Around the World in 80 Assays
- the analytical scientist — What is the Point of Analytical Science?
- the analytical scientist — Why Start-ups Need Analytical Science
- ICH M15 Guideline
- Bioanalytical Method Validation for Biomarkers | FDA
- ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer - PubMed
- Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial - PubMed
- FDA Advances Drug Development Innovation by Establishing ISTAND as Permanent Qualification Program | FDA
- Introduction to the 3RsC's cross-platform microphysiological systems evaluation for drug-induced liver injury in collaboration with FDA-CDER - PubMed
- Assay Guidance Manual Program
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
About the Author(s)
James Strachan
Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
